Last reviewed · How we verify

NCT05957562: EArAzygousvp

Azygos Vein Preservation; Its Impact on Early Outcomes After Neonatal EA/TOF Repair

Completed NA Last updated 24 July 2023
What this trial tests

NA trial testing EA/TOF primary repair with Azygos vein preservation in Azygos Vein Preservation Versus Disconnection in 64 participants. Completed in 9 April 2023.

Timeline
10 April 2020
Primary endpoint
6 October 2022
9 April 2023

Quick facts

Lead sponsordr. Muhammad Abdelhafez Mahmoud, MD
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment64
Start date10 April 2020
Primary completion6 October 2022
Estimated completion9 April 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

dr. Muhammad Abdelhafez Mahmoud, MD

Who can join

Adults 1 Day to 28 Days, any sex, with Azygos Vein Preservation Versus Disconnection or Tracheo-Esophageal Fistula With Atresia of Esophagus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Azygos vein preservation revisited: impact on early outcomes after repair of Esophageal atresia/ Tracheo-Esophageal Fistula in newborns. A randomized controlled study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Azygos vein preservation revisited: impact on early outcomes after repair of esophageal atresia/tracheoesophageal fistula in newborns.
    Daboos M, Abdelmaboud M, Hussein M, Salama A, et al · · 2023 · cited 2× · PMID 37945968 · DOI 10.1007/s13304-023-01684-4

Verify or expand the search:

Other dr. Muhammad Abdelhafez Mahmoud, MD trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05957562.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing